Business Context and Reporting Period
This Form 8-K filing by Altimmune, Inc. covers the date of May 4, 2017. The report details the adoption of a new Code of Business Conduct and Ethics by the Company's board of directors, applicable to directors, officers, employees, and consultants.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and does not contain financial statement data.
Material Changes
The primary material change is the implementation of a new Code of Ethics. This new code generally addresses the same matters as the former code previously in effect for PharmAthene, Inc., prior to the completion of the Mergers announced in a separate Form 8-K filed on May 8, 2017.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies are detailed in this document other than the standard governance update. The new Code of Ethics is available on the Company's website under "Investors - Corporate Governance."
Investor Verification Checklist
- Verify the full text of the new Code of Business Conduct and Ethics on the Altimmune website.
- Review the separate Form 8-K filed on May 8, 2017, for details regarding the Mergers with PharmAthene, Inc.
- Confirm the effective date of the new code relative to the merger completion.